1. Home
  2. LADR vs DVAX Comparison

LADR vs DVAX Comparison

Compare LADR & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LADR
  • DVAX
  • Stock Information
  • Founded
  • LADR 2008
  • DVAX 1996
  • Country
  • LADR United States
  • DVAX United States
  • Employees
  • LADR N/A
  • DVAX N/A
  • Industry
  • LADR Real Estate Investment Trusts
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • LADR Real Estate
  • DVAX Health Care
  • Exchange
  • LADR Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • LADR 1.5B
  • DVAX 1.7B
  • IPO Year
  • LADR 2014
  • DVAX 2004
  • Fundamental
  • Price
  • LADR $11.14
  • DVAX $12.76
  • Analyst Decision
  • LADR Buy
  • DVAX Buy
  • Analyst Count
  • LADR 6
  • DVAX 2
  • Target Price
  • LADR $13.33
  • DVAX $22.00
  • AVG Volume (30 Days)
  • LADR 643.0K
  • DVAX 1.4M
  • Earning Date
  • LADR 02-06-2025
  • DVAX 02-20-2025
  • Dividend Yield
  • LADR 8.22%
  • DVAX N/A
  • EPS Growth
  • LADR N/A
  • DVAX N/A
  • EPS
  • LADR 0.76
  • DVAX 0.15
  • Revenue
  • LADR $257,005,000.00
  • DVAX $260,810,000.00
  • Revenue This Year
  • LADR N/A
  • DVAX $21.64
  • Revenue Next Year
  • LADR N/A
  • DVAX $19.81
  • P/E Ratio
  • LADR $14.67
  • DVAX $84.67
  • Revenue Growth
  • LADR N/A
  • DVAX N/A
  • 52 Week Low
  • LADR $10.10
  • DVAX $9.74
  • 52 Week High
  • LADR $12.48
  • DVAX $14.71
  • Technical
  • Relative Strength Index (RSI)
  • LADR 37.23
  • DVAX 50.03
  • Support Level
  • LADR $11.07
  • DVAX $12.76
  • Resistance Level
  • LADR $11.97
  • DVAX $13.12
  • Average True Range (ATR)
  • LADR 0.24
  • DVAX 0.30
  • MACD
  • LADR -0.04
  • DVAX -0.04
  • Stochastic Oscillator
  • LADR 11.17
  • DVAX 35.20

About LADR Ladder Capital Corp

Ladder Capital Corp is an internally-managed real estate investment trust that is in commercial real estate finance. The company originates and invests in a diverse portfolio of commercial real estate and real estate-related assets, focusing on senior secured assets. The company's investment activities include: (i) Primary business of originating senior first mortgage fixed and floating rate loans collateralized by commercial real estate with flexible loan structures; (ii) owning and operating commercial real estate, including net leased commercial properties; and (iii) investing in investment-grade securities secured by first mortgage loans on commercial real estate. The company has three reportable segments include loans: which derives maximum profit; securities; and real estate.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: